Key terms

About CRSP

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest CRSP news

Today 4:30am ET Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Apellis Pharmaceuticals (APLS) Mar 14 12:50pm ET Cantor Fitzgerald biotech analysts hold an analyst/industry conference call Mar 14 11:41am ET Cantor Fitzgerald biotech analysts hold an analyst/industry conference call Mar 13 8:40am ET Crispr Therapeutics proposes to elect Christian Rommel to board of directors Mar 06 7:02am ET Crispr Therapeutics price target raised to $99 from $82 at Mizuho Feb 27 7:47am ET Crispr Therapeutics AG (CRSP) Receives a Buy from Truist Financial Feb 25 11:40pm ET Analysts Are Bullish on These Healthcare Stocks: IDEAYA Biosciences (IDYA), Insulet (PODD) Feb 22 10:25am ET Crispr Therapeutics call volume above normal and directionally bullish Feb 22 9:33am ET Crispr Therapeutics price target raised to $66 from $57 at RBC Capital Feb 22 7:40am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Crispr Therapeutics AG (CRSP), Alcon (ALC) and Outset Medical (OM) Feb 22 7:24am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Community Health (CYH), Crispr Therapeutics AG (CRSP) and Ansell (OtherANSLF) Feb 22 7:11am ET Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Arcus Biosciences (RCUS) and United Therapeutics (UTHR) Feb 22 7:04am ET Crispr Therapeutics price target raised to $70 from $55 at Wells Fargo Feb 22 5:31am ET Crispr Therapeutics price target raised to $80 from $61 at Barclays Feb 22 5:12am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Medtronic (MDT), Icon (ICLR) and Crispr Therapeutics AG (CRSP) Feb 21 6:35pm ET Buy Rating for Crispr Therapeutics AG: Strong Financials and Promising Gene-Editing Pipeline Feb 21 6:26pm ET Crispr Therapeutics price target raised to $112 from $110 at Chardan Feb 21 12:45pm ET Strong Buy Rating for Crispr Therapeutics AG on Robust Financials and Positive Casgevy Outlook Feb 21 12:00pm ET Analysts Offer Insights on Healthcare Companies: Prophase Labs (PRPH) and Crispr Therapeutics AG (CRSP) Feb 21 11:25am ET Buy Rating Affirmed for Crispr Therapeutics AG on Robust Pipeline and Expanding Global Reach Feb 21 10:30am ET Analysts Conflicted on These Healthcare Names: Globus Medical (GMED) and Crispr Therapeutics AG (CRSP) Feb 21 7:34am ET Crispr Therapeutics reports Q4 EPS $1.10, consensus (7c) Feb 20 1:34pm ET Crispr Therapeutics options imply 7.2% move in share price post-earnings Feb 15 1:36am ET Crispr Therapeutics AG: Buy Rating Affirmed Amid Clinical Milestones and Strong Financial Position Feb 14 7:16pm ET Crispr Therapeutics initiated with a Peer Perform at Wolfe Research Feb 14 4:18pm ET Crispr Therapeutics initiated with a Peer Perform at Wolfe Research Feb 13 8:07pm ET Cathie Wood’s ARK Investment bought 280K shares of Crispr Therapeutics today Feb 13 5:44pm ET Crispr Therapeutics Secures Funding Through Share Issuance Feb 13 12:35pm ET Buy Rating Affirmed for Crispr Therapeutics with Increased Price Target Following EU Approval and Capital Boost Feb 13 6:43am ET Crispr Therapeutics’ Gene Therapy Wins EU Approval Feb 09 10:45am ET Crispr Therapeutics call volume above normal and directionally bullish

No recent press releases are available for CRSP

CRSP Financials

1-year income & revenue

Key terms

CRSP Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

CRSP Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms